Form D · Biotechnology
Neurovance, Inc.
Cambridge, MA · CIK 0001544176
Offering snapshot reported Jan 6, 2017 · SEC filing
- Reported sold
- $554K Offering amount: $554K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 23, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 6, 2017 | Initial | $554,280 | No comparison | 1 | SEC filing |
| Dec 1, 2016 | Amendment | $7,500,000 | $6,500,000vs Mar 2, 2016 | 7 | SEC filing |
| Jul 15, 2016 | Amendment | $6,000,000 | $5,000,000vs Mar 2, 2016 | 7 | SEC filing |
| Mar 2, 2016 | Initial | $1,000,000 | No comparison | 7 | SEC filing |
| Jun 29, 2015 | Amendment | $26,499,997 | $23,499,997vs Oct 15, 2012 | 7 | SEC filing |
| Mar 25, 2015 | Amendment | $20,000,002 | $5,499,459vs Aug 29, 2014 | 7 | SEC filing |
| Aug 29, 2014 | Amendment | $14,500,543 | $7,000,003vs Oct 15, 2013 | 7 | SEC filing |
| Aug 29, 2014 | Amendment | $14,500,543 | $7,000,003vs Oct 15, 2013 | 7 | SEC filing |
| Mar 31, 2014 | Amendment | $10,500,543 | $3,000,003vs Oct 15, 2013 | 7 | SEC filing |
| Oct 15, 2013 | Amendment | $7,500,540 | $1,500,540vs Apr 24, 2013 | 7 | SEC filing |
| Apr 24, 2013 | Amendment | $6,000,000 | $3,000,000vs Oct 15, 2012 | 7 | SEC filing |
| Oct 15, 2012 | Initial | $3,000,000 | No comparison | 7 | SEC filing |
| May 30, 2012 | Amendment | $478,064 | $314,601vs Mar 16, 2012 | 7 | SEC filing |
| Mar 16, 2012 | Initial | $163,463 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-277876
Source: Form D, filed Jan 6, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Bailey | Director, Executive |
| Andrew Baker | Director |
| T Imothy J. Barberich | Director |
| Timothy J. Barberich | Director |
| Gregg Beloff | Executive |
| Greg Beloff | Executive |
| Franklin P. Bymaster | Executive |
| Joshua Funder | Director |
| Frank Gentile | Director |
| Brian Goff | Director, Executive |
| Timothy Hsu | Executive |
| Anthony A. Mc Kinney | Executive |
| Campbell Murray | Director |
| Daniel Omstead | Director |
| William T. Pappafotopoulos | Executive |
| Walter Piskorski | Executive |
| Ross A. Reife | Executive |
| Brigitte Robertson | Executive |
| Thomas A. Shea | Executive |
| Brigitte Smith | Director |
| Albert L. Sokol | Executive |
| Pierre Tran | Executive |
| Paul Weiss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
43 Thorndike Street Suite S1 3
Cambridge, MA, 02141
Cambridge, MA, 02141